Article
Oncology
Haowei Wang, Lei Cheng, Chao Zhao, Fei Zhou, Tao Jiang, Haoyue Guo, Jinpeng Shi, Peixin Chen, Zhuoran Tang, Shiqi Mao, Keyi Jia, Lingyun Ye, Chenlei Cai, Xuefei Li, Xiaoxia Chen, Caicun Zhou
Summary: This study examined the role of immune checkpoint inhibitors (ICI) in patients with BRAF-mutant non-small cell lung cancer (NSCLC). The results showed that ICI combined with chemotherapy had a median progression-free survival (PFS) of 12.6 months and an overall response rate (ORR) of 44%. Compared to the non-ICI therapy group, ICI combined therapy demonstrated better clinical benefits in first-line treatment.
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Review
Immunology
Saulo Brito Silva, Carlos Wagner S. Wanderley, Leandro Machado Colli
Summary: Cancer cells have genomic instability due to accumulated DNA damage. Multiple DNA damage repair pathways exist to address DNA damage during different cell cycle stages. Immunological checkpoint inhibitors have shown great efficacy in tumors with mismatch repair deficiency, but there are differences in efficacy and resistance to treatment in tumors with homologous recombination deficiency.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Felix C. Saalfeld, Carina Wenzel, Petros Christopoulos, Sabine Merkelbach-Bruse, Timm M. Reissig, Silke Lassmann, Sebastian Thiel, Jan A. Stratmann, Ralf Marienfeld, Johannes Berger, Alexander Desuki, Janna-Lisa Velthaus, Diego Kauffmann-Guerrero, Albrecht Stenzinger, Sebastian Michels, Thomas Herold, Michael Kramer, Sylvia Herold, Amanda Tufman, Sonja Loges, Jurgen Alt, Maria Joosten, Gerlinde Schmidtke-Schrezenmeier, Martin Sebastian, Susann Stephan-Falkenau, Cornelius F. Waller, Marcel Wiesweg, Juergen Wolf, Michael Thomas, Daniela E. Aust, Martin Wermke
Summary: In this study, the efficacy of ICIs in HER2mu NSCLC patients was retrospectively evaluated, showing that ICI monotherapy and combination with chemotherapy had good efficacy. In treatment-naive patients, ICI in combination with chemotherapy showed a high overall response rate, progression-free survival, and overall survival rate at 1 year.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Christine Son, Melissa Y. Y. Moey, Paul R. Walker, Abdul R. Naqash, Matthew Sean Peach, Andrew W. Ju
Summary: In this retrospective study, data was collected on Stage III-IV lung cancer patients who received immune checkpoint inhibitors (ICIs) between 2015 and 2018. The risk of cardiotoxicity was assessed in patients who received thoracic radiotherapy compared to those who did not, and no significant difference was found in the occurrence of cardiotoxicities between the two groups.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Jin Yang, Ran Zeng, Jianping Zhou, Lifeng Luo, Mengchen Lyu, Fang Liu, Xianwen Sun, Ling Zhou, Xiaofei Wang, Zhiyao Bao, Wei Chen, Daphne W. Dumoulin, Beili Gao, Yi Xiang
Summary: This study aimed to explore the efficacy, prognosis, and safety of patients with advanced lung cancer who received immune checkpoint inhibitor rechallenge. The findings suggest that rechallenge may be an attractive option for patients who discontinued treatment due to immune-related adverse events, but further research is needed for patients with disease progression.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Youwei Lu, Fengying Wu, Qiuyi Cao, Yu Sun, Moli Huang, Jing Xiao, Bin Zhou, Liang Zhang
Summary: In lung adenocarcinoma (LUAD) patients with EGFR-activating mutations, decreases in CD8(+) TILs density and function, downregulation of PD-L1, and upregulation of B7-H4 were observed. B7-H4 may serve as an alternative immune-checkpoint molecule and a potential therapeutic target for LUAD with EGFR MT.
Review
Oncology
Anwen Xiong, Jiali Wang, Caicun Zhou
Summary: Lung cancer is a significant cause of morbidity and mortality in China and globally, with non-small cell lung cancer (NSCLC) being the predominant type and immune checkpoint inhibitors (ICIs) revolutionizing its treatment. Despite challenges, ICIs have shown promising antitumor efficacy in NSCLC and hold potential for future first-line treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Si Sun, Chang Liu, Chunyan Duan, Songxia Yu, Qiao Zhang, Nana Xu, Bo Yu, Xianghua Wu, Jialei Wang, Xingjiang Hu, Hui Yu
Summary: ICIs combined with chemotherapy can significantly improve progression-free survival in NSCLC patients with EGFR mutations. According to the study results, the median PFS in the ICI combined chemotherapy group is longer than that in the ICI monotherapy group, and it shows the best survival outcome in terms of 12-month survival rate and PFS. The safety profile of the combination therapy is similar to previously reported studies of chemotherapy combined with checkpoint inhibitors.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Wolfgang M. Brueckl, Martin Reck, Achim Rittmeyer, Jens Kollmeier, Claas Wesseler, Gunther H. Wiest, Petros Christopoulos, Albrecht Stenzinger, Amanda Tufman, Petra Hoffknecht, Bernhard Ulm, Fabian Reich, Joachim H. Ficker, Eckart Laack
Summary: The study evaluated the efficacy of second line docetaxel plus ramucirumab (D+R) after first line CTx+ICI therapy in metastatic NSCLC patients. Results showed D+R to be an effective and safe treatment option, with KRAS mutations associated with poorer outcomes. Further investigations are needed for KRAS mutated patients.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Ziwei Zhou, Yiming Zhao, Si Chen, Guohui Cui, Wenkui Fu, Shouying Li, Xiaorong Lin, Hai Hu
Summary: This study reveals that cisplatin induces tumor cell ferroptosis, leading to N1 neutrophil polarization in the tumor microenvironment, which in turn remodels the tumor from cold to hot through enhancing T-cell infiltration and Th1 differentiation. The combination of cisplatin with a ferroptosis activator shows a synergistic effect in chemoimmunotherapy for EGFR-mutant NSCLC, providing an effective strategy to overcome immunotherapy resistance in NSCLC patients with driver mutations.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Ali N. Chamseddine, Tarek Assi, Olivier Mir, Salem Chouaib
Summary: The plasticity and diversity of tumor-associated macrophages (TAM) play essential roles in cancer progression. TAM can shift their polarization in response to tumor microenvironment cues, promoting or halting cancer development. However, TAM's immunosuppressive functions contribute to resistance to immune checkpoint inhibitors (ICI). Targeting TAM modulation in combination with ICI shows potential for optimizing ICI efficacy.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Immunology
Han Liu, Sean X. Luo, Jing Jie, Liping Peng, Shuai Wang, Lei Song
Summary: In recent years, immune checkpoint inhibitors (ICIs) have shown significant growth in anti-cancer treatment, particularly in lung cancer. However, the use of ICIs has also led to an increase in adverse respiratory events. This meta-analysis investigates ICIs-related respiratory disorders in lung cancer patients and suggests that ICIs-based treatments can raise the incidences of respiratory disorders. It emphasizes the need for a comprehensive consideration when conducting ICIs treatment to prevent ICIs-related respiratory disorders.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Hrishi Varayathu, Vinu Sarathy, Beulah Elsa Thomas, Suhail Sayeed Mufti, Radheshyam Naik
Summary: Immune checkpoint inhibitor therapy has revolutionized cancer immunotherapy, but not all patients respond to it. Current research is focused on combining immune checkpoint inhibitors with other drugs to explore more effective therapeutic strategies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Qu Xie, Can Hu, Cong Luo
Summary: This study found that ICI treatment induced changes in peripheral blood lymphocyte subsets in HCC patients, with an increase in CD3(+)CD8(+) T cells and a decrease in B cells percentages. Furthermore, a high percentage change in NK cells predicted longer PFS and OS in advanced HCC patients treated with ICI.
Review
Biochemistry & Molecular Biology
Giuseppe Bronte, Donato Michele Cosi, Chiara Magri, Antonio Frassoldati, Lucio Crino, Luana Calabro
Summary: In the past decade, immune checkpoint inhibitors (ICIs) have brought significant clinical and survival improvements in various settings of advanced non-small-cell lung cancer (NSCLC). However, their efficacy in specific NSCLC subpopulations, such as elderly patients with active brain metastases or oncogene-addicted mutations, remains controversial due to their exclusion or underrepresentation in pivotal phase III studies. Additionally, there are currently no predictive biomarkers available to aid in patient selection for this therapeutic approach. This article critically summarizes the current state of ICI efficacy in the most common special NSCLC subpopulations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
